Research Article Open Access

In Vitro Activity of Tigecycline in the Era of NDM-1

Dorairajan Sureshkumar1, Ram Gopalakrishnan1 and M.A. Thirunarayan1
  • 1 Apollo Hospitals, India


In the current era of New Delhi Metallo-betalactamase-1 (NDM-1) infections and a dry antibiotic pipeline, managing infections caused by Multi-Drug Resistant Gram-Negative Bacterial infections (MDR-GNBs) presents a great challenge to physicians in the developing world. Tigecycline, a broad spectrum glycylcycline is a one among the few treatment options against MDR-GNBs. However it has been studied mostly in the western world, where the prevalence of MDR-GNB infections is less than the developing world. In this study, we report the in vitro activities of tigecycline and selected antimicrobials against gram-negative bacterial isolates. We evaluated the in vitro activity of tigecycline against 80 gram-negative bacterial isolates and compared its susceptibility against Cefoperazone-Sulbactam (CS), imipenem and colistin in a tertiary care hospital in South India. Tigecycline showed 100% activity against E.coli, similar to colistin and better than impenem and cefoperazone-sulbactam. However only 80% of Klebsiella pneumoniae isolates remained susceptible to tigecycline and colistin had higher in vitro activity against Acinetobacter. Tigecycline is a good option for the management of MDR E.coli and an alternative option against Acinetobacter infections in India. However the decline in susceptibility of tigecycline against K.pneumoniae is a worrisome phenomenon.

Current Research in Microbiology
Volume 3 No. 2, 2012, 34-36


Submitted On: 8 October 2012 Published On: 12 September 2012

How to Cite: Sureshkumar, D., Gopalakrishnan, R. & Thirunarayan, M. (2012). In Vitro Activity of Tigecycline in the Era of NDM-1. Current Research in Microbiology, 3(2), 34-36.

  • 0 Citations



  • Tigecycline
  • In Vitro
  • Antibiotic Susceptibility